Gilead Sciences consensus target USD 160.07: stock pre-market at EUR 131.97, minus 0.70 percent
Published on 10/14/2026 at 08:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDaily setup before the open
- Barchart's October 14, 2026 preview identified Gilead's upcoming third-quarter report.
- Gilead Sciences stock trades pre-market at EUR 131.97 at 8:37 a.m. CEST at Lang & Schwarz on October 14, 2026, 0.70 percent below the Xetra close of October 13, 2026.
- Barchart reported an average analyst target of USD 160.07.
Barchart's October 14, 2026 earnings preview identified Gilead Sciences' upcoming third-quarter report and cited an average analyst target of USD 160.07. At 8:37 a.m. CEST on October 14, 2026, the stock was at EUR 131.97 pre-market at Lang & Schwarz, 0.70 percent below the Xetra close of October 13, 2026 at EUR 132.90. The bid was EUR 131.72 and the ask was EUR 132.22. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.
What matters today
Barchart's October 14, 2026 preview said Gilead's third-quarter report was upcoming. A round-number level of EUR 135.00 is 2.30 percent above the Lang & Schwarz price. Barchart reported an average analyst price target of USD 160.07.
Analyst expectations
Barchart said analysts expected diluted third-quarter earnings per share of USD 2.16, compared with USD 2.47 in the year-ago quarter. The article also reported that Gilead had exceeded Wall Street's earnings estimates in each of the previous four quarters. Its analyst consensus was described as a Strong Buy, with 21 of 30 analysts assigning that rating.
Market context: Market report Nasdaq Composite.
